Trainet: Diabetes Type 1 Prevention
Trainet: Diabetes Type 1 Prevention
批准号:
8284422
负责人:
PETER A GOTTLIEB
金额:
$39.78万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2014-04-30
关键词:
AnimalsAutoantibodiesAutoimmune DiseasesC-PeptideDNA VaccinesDataDevelopmentDiabetes MellitusDiagnosisDietary InterventionDoseDouble-Blind MethodFundingFutureGlycosylated hemoglobin AGoalsHyperglycemic MiceImmuneInsulinInsulin-Dependent Diabetes MellitusMeasuresMethodsMusNatural HistoryPatientsPlacebo ControlPopulations at RiskPreventionPrincipal InvestigatorProductionProductivityProinsulinProtocols documentationRandomizedRecruitment ActivityResearchResearch DesignSafetySchemeT-LymphocyteTestingTherapeutic InterventionToxic effecthuman subjectinsulin dependent diabetes mellitus onsetnonhuman primatepatient populationphase 1 studyphase 2 studypreclinical studypreventprogramspublic health relevance
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Long-term objective: To find intervention therapies that can delay, prevent or reverse the development of type 1 diabetes (T1D).
Specific Aims:
1) BHT-3021 Proinsulin DNA vaccine treatment of recent onset type 1 diabetes subjects
Research Design: Preliminary data in animals has shown that using a similar proinsulin DNA vaccine can reverse diabetes in hyperglycemic mice. Pre-clinical studies in mice and non-human primates have found no toxicity for this therapy and have suggested a dosing scheme which could be effective in human subjects with T1D. An ongoing phase 1 study has confirmed the safety of this treatment and has suggested potential efficacy in type 1 diabetes subjects >3 months from diagnosis who still have C-peptide present. The current trial will test 2 doses, 1 and 3 mg, given weekly for 12 doses in a new onset patient population. It will use established measures to determine the effect on C-peptide, HbA1c, total insulin use and other safety parameters. Mechanistic studies to look at effects on insulin and other autoantibodies, T cells and other immune effects will be performed to better understand the potential mechanism of effect.
2) Renewal of TrialNet Center
Research Design: The Barbara Davis Center has been at the forefront of defining populations at risk for T1D and other autoimmune diseases and in recruiting patients for the TrialNet Natural History study as well as other TrialNet studies. The BDC TrialNet Center has helped to develop two of the first protocols, TN02 (MMF and DZB in new onset T1D), and TN06 (Nutritional Intervention to Prevent [NIP] Diabetes). Our proposal for renewal outlines our past efforts, current approaches and future goals to not only maintain our current level of productivity, but to increase productivity over the next funding cycle.
PUBLIC HEALTH RELEVANCE: The purpose of this research is to investigate methods to prevent diabetes and/or to prolong insulin production in people who have been recently diagnosed with type 1 diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Trainet: Diabetes Type 1 Prevention
-
批准号:7790104
-
项目类别:
-
资助金额:$56.87万
-
财政年份:2009
-
负责人:PETER A GOTTLIEB
-
依托单位:
TrialNet: Diabetes Type 1 Prevention
-
批准号:9268733
-
项目类别:
-
资助金额:$58.72万
-
财政年份:2009
-
负责人:PETER A GOTTLIEB
-
依托单位:
TrialNet: Diabetes Type 1 Prevention
-
批准号:9066681
-
项目类别:
-
资助金额:$58.72万
-
财政年份:2009
-
负责人:PETER A GOTTLIEB
-
依托单位:
TrialNet: Diabetes Type 1 Prevention
-
批准号:8919876
-
项目类别:
-
资助金额:$58.72万
-
财政年份:2009
-
负责人:PETER A GOTTLIEB
-
依托单位:
Trainet: Diabetes Type 1 Prevention
-
批准号:8831770
-
项目类别:
-
资助金额:$0.84万
-
财政年份:2009
-
负责人:PETER A GOTTLIEB
-
依托单位:
Trainet: Diabetes Type 1 Prevention
-
批准号:8490602
-
项目类别:
-
资助金额:$54.8万
-
财政年份:2009
-
负责人:PETER A GOTTLIEB
-
依托单位:
TrialNet: Diabetes Type 1 Prevention
-
批准号:8776002
-
项目类别:
-
资助金额:$60.48万
-
财政年份:2009
-
负责人:PETER A GOTTLIEB
-
依托单位:
Trainet: Diabetes Type 1 Prevention
-
批准号:7939573
-
项目类别:
-
资助金额:$60.84万
-
财政年份:2009
-
负责人:PETER A GOTTLIEB
-
依托单位:
Trainet: Diabetes Type 1 Prevention
-
批准号:8076277
-
项目类别:
-
资助金额:$61.28万
-
财政年份:2009
-
负责人:PETER A GOTTLIEB
-
依托单位:
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES
-
批准号:7719503
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2008
-
负责人:PETER A GOTTLIEB
-
依托单位:
EFFECTS OF RITUXIMAB ON THE PROGRESSION OF TYPE 1 DIABETES IN NEW ONSET SUBJECTS
-
批准号:7719536
-
项目类别:
-
资助金额:$0.01万
-
财政年份:2008
-
负责人:PETER A GOTTLIEB
-
依托单位:
EFFECTS OF RITUXIMAB ON THE PROGRESSION OF TYPE 1 DIABETES IN NEW ONSET SUBJECTS
-
批准号:7604486
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2007
-
负责人:PETER A GOTTLIEB
-
依托单位:
TRIALNET NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES
-
批准号:7605092
-
项目类别:
-
资助金额:$4.47万
-
财政年份:2007
-
负责人:PETER A GOTTLIEB
-
依托单位:
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES
-
批准号:7604453
-
项目类别:
-
资助金额:$0.3万
-
财政年份:2007
-
负责人:PETER A GOTTLIEB
-
依托单位:
TREATMENT WITH HOKT3YL (ALA-ALA) IN TYPE 1 DIABETES MELLITUS
-
批准号:7605132
-
项目类别:
-
资助金额:$1.44万
-
财政年份:2007
-
负责人:PETER A GOTTLIEB
-
依托单位:
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES
-
批准号:7605060
-
项目类别:
-
资助金额:$1.51万
-
财政年份:2007
-
负责人:PETER A GOTTLIEB
-
依托单位:
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES
-
批准号:7377865
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2006
-
负责人:PETER A GOTTLIEB
-
依托单位:
STUDY 1: TO COMPARE THE RELIABILITY OF MMT AND IV GLUCAGON STIMULATION TEST
-
批准号:7374395
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2006
-
负责人:PETER A GOTTLIEB
-
依托单位:
IMMUNOTHERAPY TRIAL FOR NEW ONSET TYPE 1 DIABETES
-
批准号:7374331
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2006
-
负责人:PETER A GOTTLIEB
-
依托单位:
LONG-TERM EFFECTS OF NBI 6024 IN TYPE 1 DIABETES SUBJECTS FROM NBI602-0003 TRIAL
-
批准号:7377794
-
项目类别:
-
资助金额:$0.03万
-
财政年份:2006
-
负责人:PETER A GOTTLIEB
-
依托单位:
海外基金